Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/19/2025

Wound Healing and Tissue Repair Guidelines

Introduction to TB-500

  • The International Working Group on the Diabetic Foot (IWGDF) does not recommend TB-500 as a treatment option for wound healing, particularly for diabetic foot ulcers, due to lack of safety and efficacy data in humans 1
  • The use of TB-500 for wound healing or tissue repair is not approved by regulatory agencies such as the FDA or EMA, and its production is unregulated, raising concerns about purity, dosing, and contaminants 2

Evidence-Based Approaches

  • The International Working Group on the Diabetic Foot (IWGDF) provides specific recommendations for wound healing interventions based on quality evidence, emphasizing evidence-based approaches over unapproved pharmacological agents 1
  • The IWGDF guidelines focus on standard of care and adjunctive therapies, such as negative pressure wound therapy (NPWT), for specific wound types, but not for non-surgical wounds 2

Standard of Care and Adjunctive Therapies

  • Guidelines from the International Working Group on the Diabetic Foot (IWGDF) emphasize that pharmacological agents that claim to stimulate healing should not be used over standard of care, and that adjunctive therapies like NPWT may be considered for post-surgical wounds, but not for non-surgical wounds 2
  • The American College of Cardiology is not mentioned in the context of wound healing guidelines, however, the International Working Group on the Diabetic Foot (IWGDF) recommends following established wound care protocols for evidence-based treatment options appropriate for specific wound types 1

Patient Education and Treatment Options

  • Patients seeking wound healing and tissue repair treatments should avoid using TB-500 due to lack of safety data, efficacy evidence, and regulatory approval, and instead follow established wound care protocols recommended by medical guidelines 2
  • Healthcare providers should educate patients about the risks of using unregulated peptides like TB-500 and direct them toward treatments with established safety and efficacy profiles, consulting with wound care specialists for evidence-based treatment options 1